AstraZeneca Pharma India shares rose 8.68% to Rs 2,879.55 after reporting a 2.6% increase in net profit to Rs 27.98 crore in Q4 FY22 from Rs 27.28 crore in Q4 FY21.

Also Read| Paradeep Phosphates share surges over 8% on debut

Net sales increased 10% year on year to Rs 231.96 crore in Q4 FY22, up from Rs 210.26 crore in Q4 FY21. Profit before tax increased by 0.5% to Rs 37.03 crore in Q4 FY22 compared to Q4 FY21.

Also Read| Sensex surges over 500 points while Nifty around 16,330 in early trade

The drugmaker’s overall spending increased 14.2% to Rs 194 crore in Q4 FY22, up from Rs 169.85 crore in the same time the previous year. Finance expenses fell 26.51% year on year to Rs 20.71 crore in the financial quarter ending March 31, 2022.

Also Read| Trending Stocks: Hindalco, Piramal, Tata Power and others in news today

In FY22, the biopharmaceutical firm reported a 34% decrease in net profit to Rs 61.59 crore on a 1% decrease in net sales to Rs 805.60 crore over FY21.

Also Read| Trade Setup: Top 13 things to know before market opens on May 27, 2022

For the fiscal year ending March 31, 2022, the board proposed a final dividend of Rs 8 per equity share. 

Also Read| Stocks that should be on your watchlist on Friday, May 27, 2022

AstraZeneca Pharma India is a multinational biopharmaceutical corporation. The company is involved in the research, development, and commercialization of medications for critical areas of healthcare such as cardiovascular/metabolic illness, cancer, respiratory, inflammatory, and autoimmune disease.